Insulet Co. (PODD) Expected to Announce Quarterly Sales of $125.25 Million

Equities research analysts expect that Insulet Co. (NASDAQ:PODD) will post sales of $125.25 million for the current quarter, according to Zacks. Ten analysts have provided estimates for Insulet’s earnings. The highest sales estimate is $127.49 million and the lowest is $124.20 million. Insulet posted sales of $103.58 million during the same quarter last year, which suggests a positive year over year growth rate of 20.9%. The company is scheduled to report its next quarterly earnings results after the market closes on Wednesday, February 21st.

According to Zacks, analysts expect that Insulet will report full-year sales of $125.25 million for the current year, with estimates ranging from $457.40 million to $460.79 million. For the next year, analysts anticipate that the firm will report sales of $556.15 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Insulet.

Several brokerages have recently issued reports on PODD. Zacks Investment Research upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Thursday, February 1st. BidaskClub upgraded Insulet from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Raymond James Financial upgraded Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Monday, January 8th. UBS Group upgraded Insulet from a “market perform” rating to an “outperform” rating in a research note on Monday, January 8th. Finally, Barclays reiterated a “buy” rating and issued a $78.00 price target on shares of Insulet in a research note on Wednesday, December 13th. Eight equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Insulet has a consensus rating of “Buy” and an average target price of $62.53.

Shares of Insulet (NASDAQ PODD) traded down $0.02 on Wednesday, hitting $76.73. The stock had a trading volume of 209,300 shares, compared to its average volume of 520,055. Insulet has a one year low of $38.43 and a one year high of $78.65. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88.

Hedge funds have recently modified their holdings of the stock. Cerebellum GP LLC bought a new stake in Insulet during the 4th quarter worth $122,000. Equitec Specialists LLC bought a new stake in Insulet during the 4th quarter worth $145,000. James Hambro & Partners bought a new stake in Insulet during the 4th quarter worth $165,000. C M Bidwell & Associates Ltd. bought a new stake in Insulet during the 4th quarter worth $188,000. Finally, Diversified Trust Co bought a new stake in Insulet during the 4th quarter worth $218,000.

TRADEMARK VIOLATION WARNING: “Insulet Co. (PODD) Expected to Announce Quarterly Sales of $125.25 Million” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/19/insulet-co-podd-expected-to-announce-quarterly-sales-of-125-25-million.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply